INSP - NYSE
Inspire Medical Systems, Inc.
$40.47
-0.27%Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, a closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.
At a Glance
Live SnapshotInspire Medical Systems, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.
CapEx Intensity
Moderate capital requirements typical of many stable businesses. Healthy balance between reinvestment and cash generation.
FCF Growth Trend
Declining FCF warrants attention. Investigate whether due to temporary factors or fundamental deterioration.
Working Capital Impact
Significant working capital drain. Growth may be consuming cash through inventory buildup or receivables extension—monitor closely.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Inspire Medical Systems, Inc. Cash Flow Statement
INSP • NYSE
| Inspire Medical Systems, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||||
145.4M | 53.5M | -21.2M | -44.9M | -42M | -57.2M | -33.2M | -21.8M | -17.5M | -18.5M | -21.3M | |
14M | 6.6M | 2.8M | 2.9M | 2M | 840K | 495K | 393K | 285K | 103K | 120K | |
-88.7M | 0.0 | 0.0 | 0.0 | 0.0 | -22K | 0.0 | -53K | 100K | -195K | 12K | |
0.0 | 116M | 82.5M | 0.0 | 0.0 | 12.8M | 6.2M | 1.2M | 243K | 248K | 305K | |
133.7M | -7.5M | 1.3M | 51.7M | 26.8M | 1.4M | 279K | 714K | 315K | 180K | 50K | |
-87.4M | -37.7M | -40.8M | 1.8M | -6.9M | -10.9M | -6.6M | 861K | 777K | 243K | -1.4M | |
117M | 130.2M | 24.7M | 11.6M | -20.1M | -53M | -32.8M | -18.7M | -15.8M | -17.9M | -22.3M | |
INVESTING ACTIVITIES | |||||||||||
-38.5M | -39.1M | -23.6M | -9.1M | -4.7M | -2.5M | -2.7M | -250K | -412K | -306K | -346K | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -89.1M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-250.4M | -418.6M | -281.4M | (0.0) | -10M | -52.7M | -178.1M | -115.5M | -9M | (0.0) | (0.0) | |
310.4M | 344.6M | 10.2M | 0.0 | 43.8M | 141.8M | 137.3M | 32.3M | 1.8M | 0.0 | 23.9M | |
0.0 | 0.0 | 0.0 | -10.5M | 0.0 | 89.1M | 0.0 | -83.1M | -7.2M | 0.0 | 23.9M | |
(21.4M) | -113.1M | -294.8M | -19.6M | (29.1M) | (86.6M) | -43.6M | -83.4M | -7.6M | -306K | (23.6M) | |
FINANCING ACTIVITIES | |||||||||||
-160.4M | -47.2M | 31.1M | 259.6M | 14.9M | 124.7M | 0.0 | 181.8M | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | -24.5M | 0.0 | 0.0 | 0.0 | 8M | 458K | 0.0 | 2.5M | |
-175M | -75M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-23M | -5.2M | -17.2M | -43K | 0.0 | 9.4M | 2M | 558K | 235K | 466K | 42K | |
-183.4M | -52.4M | 14M | 235.1M | 14.9M | 134.1M | 2M | 190.4M | 25.7M | 12.8M | 2.5M | |
CASH FLOW SUMMARY | |||||||||||
-310K | -118K | 164K | 75K | -19K | 11K | 13K | 33K | 0.0 | 0.0 | 0.0 | |
-45.3M | -35.4M | -256.1M | 227.1M | 23.9M | 167.7M | -74.4M | 88.3M | 2.3M | -5.4M | 3.9M | |
150.2M | 185.5M | 441.6M | 214.5M | 190.5M | 22.9M | 97.3M | 9M | 6.7M | 12.1M | 8.3M | |
104.8M | 150.2M | 185.5M | 441.6M | 214.5M | 190.5M | 22.9M | 97.3M | 9M | 6.7M | 12.1M | |
78.5M | 91.1M | 1M | 2.5M | -24.8M | -55.5M | -35.6M | -18.9M | -16.2M | -18.3M | -22.6M |
SEC Filings
INSP - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 05, 2026 | April 30, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 04, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 04, 2026 | May 04, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | March 20, 2026 | April 30, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 13, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 11, 2026 | February 05, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 09, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 17, 2025 | November 17, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 03, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 03, 2025 | November 03, 2025 | 2025 |
Related Guides
Continue your INSP research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.